Clinical Trial Update: Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing feasibility of olanzapine at reduced dose for highly emetogenic chemotherapy; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: CR-CSSS Champlain-Charles-Le Moyne | Conditions: Chemotherapy-induced Nausea and Vomiting | Phase 3 | Status: COMPLETED